Gender and risk assessment in contraceptive technologies

Sociology of Health and Illness

Volumn 24, Issue 4, 2002, Pages 436-461

  Van Kammen, Jessika ^a   Oudshoorn, Nelly ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Contraceptives; Gender; Risk assessment

Indexed keywords

CHEMICAL COMPOUND; CONTRACEPTIVE AGENT;

ANALYSIS; ARTICLE; CONTRACEPTION; DRUG EFFECT; EVALUATION; GENDER; HEALTH HAZARD; HORMONAL CONTRACEPTION; HUMAN; LIBIDO; MENTAL HEALTH; RATING SCALE; RESEARCH; RISK ASSESSMENT; SEXUALITY; WELLBEING;

EID: 0036661776     PISSN: 01419889     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-9566.00303     Document Type: Article

References (87)

1. Abraham, J. and Sheppard, J. (1999) Complacent and conflicting scientific expertise in British and American drug regulation: Clinical risk assessment of Triazolam, Social Studies of Science, 29, 6, 803-45.
2. Abraham, J. and Sheppard, J. (1998) International comparative analysis and explanation in medical sociology, Sociology, 32, 141-62.
3. Abraham, J. (1994a) Distributing the benefit of the doubt: Scientists, regulators, and drug safety, Science, Technology and Human Values, 19, 4, 493-522.
4. Abraham, J. (1994b) Bias in science and medical knowledge, Sociology, 28, 717-36.
5. Aldhous, P. (1990) Equality for the sexes? Nature, 25 October, 347, 701.
6. Babiak, J. and Rudel, L.L. (1987) Lipoproteins and atherosclerosis, Bailliere's Clinical Endocrinological Metabolism, 1, 515-50.
7. Bain, J., Rachlis, V., Robert, E. and Khait, Z. (1980) The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme, Contraception, 21, 4, 365-79.
8. Berer, M., and Ravindran, S. (1994) Open letter to WGNRR, Women's Global Network for Reproductive Rights Newsletter, 48, 14-17.
9. Bromhan, D.R. (1992) Contraceptive implants, British Medical Journal, 312, 1555-6.
10. Bruce, J. (1987) Users' perspectives on contraceptive technology and delivery systems; highlighting some feminist issues, Technology in Society, 9, 359-83.
11. Bygdeman, M. (1994) Progress report clinical trial. Unpublished paper.
12. Check, W. (1999) Stripping away cultural taboos. The Kinsey Institute for research into sex, gender and reproduction, Orgyn. Organon's Magazine on Women and Health, 1, 18-24
13. Clarke, A. (1998) Disciplining Reproduction: Modernity, American Life Sciences and the Problem of Sex. Berkely: University of California Press.
14. Cottingham, J. (ed) (1997) Beyond Acceptability: Users' Perspectives on Contraceptives. London: Reproductive Health Matters and the World Health Organization.
15. Cravioto, M.C., Alvarado, G., Canto-de-Cetina, T., Bassol, S., Oropeza, G., Santos Yung, R., Valencia, J., Palma, Y., Fuziwara, J.L., Navarrete, T., Garza Flores, J. and Perez Palacios, G. (1997) A multicenter comparative study on the efficiency, safety and acceptability of contraceptive subdermal implants Norplant and Norplant-2, Contraception, 55, 359-67.
16. Davidson, A.R., Ahn, K., Chandra, S., Diaz-Guerro, R., Dubey, D.C. and Mehryar, A. (1985) Contraceptive Choices for Men: Existing and Potential Male Methods. Report prepared for presentation at the Seminar on Determinants of Contraceptive Method Choice, 26-29 August, East West Population Institute Honolulu, Hawaii.
17. Diller, L. and Hembree, W. (1977) Male contraception and family planning: A social and historical review, Fertility and Sterility, 28, 12, 1271-79.
18. Djerassi, C. (1989) The bitter pill, Science, 245, 356-61.
19. Fraser, I.S., Tiitinen, A., Affandi, B., Brache, V., Croxiatto, H.B., Diaz, S., Ginsburg, J., Gu, S., Holma, P., Johansson, E., Meirik, O., Mishell, D.R., Nash, H.A., Von Schoultz, B. and Sivin, I. (1998) Norplant consensus statement and background review, Contraception, 57, 1-9.
20. Gabe, J. (1995) Health, medicine and risk: The need for a sociological approach. In Gabe, J. (ed) Medicine, Health and Risk. Sociological Approaches. In Sociology of Health and Illness Monograph Series, Oxford: Blackwell.
21. Garcia, G. and Dacach, S. Norplant 5 years later. (1991) In Mintzes, B. (ed) A Question of Control, Women's Perspectives on the Development and Use of Contraceptive Technologies, Amsterdam: Wemos, Women and Pharmaceuticals Project and Health Action International.
22. Gelijns, A. and Pannenborg, C. (1993) The development of contraceptive technology: Case studies of incentives and disincentives of innovation, International Journal of Technology Assessment in Health Care, 9, 2, 210-32.
23. Gifford, S.M. (1986) The meaning of lumps: A case study of the ambiguities of risk. In Janes, C.R., Stall, R., Giffirds, G.M. (eds) Anthropology and Epidemiology. Interdisciplinary Approaches to the Study of Health and Disease. Dordrecht: D. Reidel Publishing Company.
24. Gombe, S. (1983) A review of the current status in male contraceptive studies, East African Medical Journal, 60, 4, 203-11.
25. Graham, C.A., Ramos, R., Bancroft, J., Maglaya, C. and Farley, T.M.M. (1995) The effects of steroidal contraceptives on the well being and sexuality of women: A double blind, placebo controlled, two-center study of combined and progesterone-only methods, Contraception, 52, 363-69.
26. Greep, R.O. and Koblinsky, M.A. (eds) Frontiers in Reproduction and Fertility Control: A Review of the Reproductive Sciences and Contraceptive Development, Cambridge, Massachusetts, and London: MIT Press: 458-65.
27. Griffin, P.D. (1988) Vaccines for fertility regulation. In Research in Human Reproduction: Biennial Report 1986-1987, Geneva: WHO, 177-97.
28. Griffin, P.D., Jones, W.R. and Stevens, V.C. (1994) Anti-fertility vaccines: Current status and implications for family planning programmes, Reproductive Health Matters, 3, 70-5.
29. Handelsman, D.J. (1991) Bridging the gender gap in contraception: Another hurdle cleared, The Medical Journal of Australia, 154, 4, 230-33.
30. Hanhart, J. (1999) Bijwerkingen zijn normaal; maar wie beslis-t dat? MSc-thesis Medical Anthropology, University of Amsterdam.
31. Hardon, A.P. (1992) The needs of women versus the interests of family planning personnel, policy-makers and researchers: Conflicting views on safety and acceptability of contraceptives, Social Science and Medicine, 6, 35, 753-66.
32. Hardon, A. (1997) Women's views and experiences of hormonal contraceptives: What we know and what we need to find out. In Cottinham, J. (ed) Beyond Acceptability: Users' Perspectives on Contraception. London: Reproductive Health Matters and the World Health Organization.
33. Hardon, A. and Hayes, E. (eds) (1997) Reproductive Rights in Practice. A Feminist Report on the Quality of Care. London and New York: Zed Books.
34. Harrison, P.F. and Rosenfield, A. (1998) Research, introduction and use: Advancing from Norplant, Contraception, 58, 323-34.
35. Hartmann, B. (1987) Reproductive Rights and Wrongs. The Global Politics of Population Control and Contraceptive Choice. New York: Harper and Row.
36. International Women's Health Coalition (1994) Women's Voices '94. Women's Declaration on Population Policies. Report in Preparation for the 1994 International Conference on Population and Development. New York.
37. Kammen, J. van (2000) Conceiving Contraceptives. The Involvement of Users in Antifertility Vaccines Development. Amsterdam: Dissertation University of Amsterdam.
38. Kirejczyk, M. (2000) Enculturation through script selection. Political discourse and practice of in vitro fertilization in the Netherlands. In Saetnan, A., Oudshoorn, N., and Kirejczyk, M. (eds) Bodies of Technology. Women's Involvement in Reproductive Medicine. Columbus: Ohio State University Press.
39. Kretser, D.M. de. (1974) The regulation of male fertility. The state of the art and future possibilities, Contraception, 9, 6, 561-600.
40. Lane, K. (1995) The medical model of the body as a site of risk: A case study of childbirth. In Gabe, J. (ed) Medicine, Health and Risk. Sociological Approaches. Sociology of Health and Illness Monograph Series. Oxford: Blackwell, 1995.
41. Latour, Bruno (1987) Science in Action: How to Follow Scientists and Engineers Through Society. Milton Keynes: Open University Press.
42. Law, J. (1988) On the art of representation: Notes on the politics of visualization. In Fyfe, G. and Law, J. (eds) Picturing Power. Visual Depiction and Social Relations. London, New York: Routledge.
43. Mastroianni, L., Donaldson, P.J. and Kane, T.T. (1990) Development of contraceptives. Obstacles and opportunities, The New England Journal of Medicine, 322, 482-85.
44. Maugh, T.H. (1981) Male 'pill' blocks sperm enzyme, Science, 212, 4492, 314.
45. Michel, E., Bents, H., Bint Akhtar, Fatima et al. (1985) Failure of high-dose sustained release luteinizing hormone releasing hormone agonist (Buserelin) plus oral testosterone to suppress male fertility, Clinical Endocrinology, 23, 663-5.
46. Mintzes, B. (ed) (1991) A Question of Control. Women's Perspectives on the Development and Use of Contraceptive Technologies. Amsterdam: Wemos Women and Pharmaceutical Project and Health Action International.
47. Mintzes, B., Hardon, A. and Hanhart, J. (1993) Norplant: Under her Skin. Amsterdam: Women and Pharmaceuticals Project, WHAF/WEMOS.
48. Nettleton, S. and Watson, J. (eds) (1997) The Body in Everyday Life. London: Routledge.
49. Ollila, E. and Hemminki, E. (1997) Does licensing of drugs in industrialized countries guarantee drug quality and safety for Third World countries? The case of Norplant licensing in Finland, International Journal of Health Services, 27, 2, 309-28.
50. Oudshoorn, N. (1999) On masculinities, technologies, and pain. The testing of male contraceptive technologies in the clinic and the media, Science, Technology and Human Values, 24, 2, 265-89.
51. Oudshoorn, N. (2002) Drugs for healthy people. The clinical testing of hormonal contraceptives for women and men. In Van Heteren, G.M. and Tansey, E.M. (eds) Biographies of Remedies: Drugs, Medicines, and Contraceptives in Dutch and Anglo-American Healing Cultures, Amsterdam, Atlanta, GA.: Rodopi, 79-92.
52. Oudshoorn, N. (2003) Designing Technology and Masculinity. A Biography of the Male Pill. Durham NC: Duke University Press.
53. Paulsen, C.A. (1977) Regulation of male fertility, in Greep, R.O. and Koblinsky, M.A. (eds) Frontiers in Reproduction and Fertility Control. A Review of the Reproductive Sciences and Contraceptive Development, Cambridge, Massachusetts, and London: MIT Press: 458-65.
54. Pavlou, S.N., Brewer, K., Farley, M.G. et al. (1991) Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido, Journal of Clinical Endocrinology and Metabolism, 73, 6, 1360-69.
55. Pitanguy, J. (1994) Feminist politics and reproductive rights: The case of Brazil. In Sen, G. and Snow, R. (eds) Power and Decision; the Social Control of Reproduction, Boston, USA: Harvard University Press.
56. Ploeg, I. van der (1998) Prosthetic Bodies. Female Embodiment in Reproductive Technologies, Ph.D. Dissertation University of Maastricht. The Netherlands.
57. Population Council (1990) Annual Report. New York: The Population Council.
58. Program for Appropriate Technology in Health (1993) Enhancing the Private Sector's Role in Contraceptive Research and Development. Seattle, Washington: PATH.
59. Rabe, T., Thuro, H.C., Goebel, K. et al. (1992) Lipid metabolism in Norplant-2 users. A two-year follow-up study, Contraception, 45, 21-28.
60. Richards, E. (1988) The politics of therapeutic evaluation: The vitamin C and cancer controversy, Social Studies of Science, 18, 4, 653-701.
61. Rogers, A. and Pilgrim, D. (1995) The risk of resistance: Perspectives on the mass childhood immunisation programme. In Gabe, J. (ed) Medicine, Health and Risk. Sociological Approaches. Sociology of Health and Illness Monograph Series. Oxford: Blackwell.
62. Schally, A.W. and Comura-Schally, A.M. (1987) Male contraception involving testosterone supplementation: Possible increased risks of prostate cancer? The Lancet, 21 February, 448.
63. Scrip (1997) Number 2206 February 14th. PJB Publications Ltd.
64. Seaman, Barbara (1969) The Doctor's Case Against the Pill. New York: P.H. Wyden.
65. Seaman, Barbara and Seaman, G. (1978) Women and the Crisis in Sex Hormones. An Investigation of the Dangerous Uses of Hormones: From Birth Control to Menopause and the Safe Alternatives, Brighton, Sussex: Harvester.
66. Shah, I. (1995) Perspectives on Methods of Fertility Regulation: Setting a Research Agenda: A Background Paper. (Unpublished paper).
67. Shapin, S. (1994) A Social History of Truth: Civility and Science in Seventeenth Century England. Chicago: Chicago University Press.
68. Sihvo, S., Ollila, E. and Hemminki, E. (1995) Perceptions and satisfaction among Norplant users in Finland, Acta Obstetricia Gynecologica Scandinavica, 74, 441-5.
69. Sivin, I. (1988) International experience with Norplant and Norplant-II contraceptive implants, Studies in Family Planning, 19, 81-94.
70. Skoglund, R.D. and Paulsen, A.A. (1973) Danazol Btestosterone Combination: A Potentially Effective means for Reversible Male Contraception, a Preliminary Report, 7, 5, 357-65.
71. Stokes, B. (1980) Men and family planning, Worldwatch Paper, December, 41.
72. Su-Juan, G., Ming-Kun, D., Ling-De, Z., Ying-Lin, L., Shu-Hua, W. and Sivin, I. (1994) A 5-year evaluation of Norplant contraceptive implants in China, Obstetrics and Gynaecology, 83, 5, 673-78.
73. Swerdloff, R.S., Arthur Campfield, L., Anselmo, Palacios and Dale McClure, R. (1979) Suppression of human spermatogenesis by depot androgen: Potential for male contraception, Journal of Steroid Biochemistry, 11, 663-70.
74. Szarewski, A. (1999) The hormonal contraceptive cafetaria. In search of perfect birth control, Orgyn. Organon's Magazine for Women and Health, 2, 38-42.
75. Talwar, G.P., Hingorani, V., Kumar, S., Roy, S. et al. (1990) Phase I clinical trials with three formulations of anti hCG vaccine, Contraception, 41, 3, 301-16.
76. Talwar, G.P., Singh, O., Pal, R., Chatterjee, N. et al. (1993) A birth control vaccine is on the horizon for family planning, Annals of Medicine, 25, 207-12.
77. Tom, L., Bhasin, S., Salameh, W. et al. (1992) Induction of azoospermia in normal men with combined nal-glu gonadotropin-releasing antagonist and testosterone enanthate, Journal of Clinical Endocrinology and Metabolism, 75, 2, 476-83.
78. United Nations (1984) International Conference on Population, Mexico City. Recommendations for the further implementation of the World Population Plan of Action, August 1984.
79. United Nations (1994) International Conference on Population and Development. Program of Action. New York.
80. Vennix, Paul (1990) De pil en haar alternatieven. NISSO studies. Utrecht: Eburon.
81. Wallace, E.M. and Wu. F.C.W. (1990) Effect of depot medroxyprogesterone acetate and testeosterone oenanthate on serum lipoproteins in man, Contraception, 41, 1, 63-71.
82. WHO (1982) World Health Organization task force on psychosocial research in family planning and the programme of research, development, and training in human reproduction. Hormonal contraception for men: Acceptability and effects on sexuality. Studies in Family Planning, 13, 11, 328-42.
83. WHO (1988) WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Methods for the Regulation of Male Fertility. IN-DEPTH Report for the scientific and technical review committee (STRC) 29 February - 4 March 1988.
84. WHO (1990) WHO Task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet, 1990, 336, 8721, 955-9.
85. WHO/HRP (1996) Annual Technical Report 1995. Geneva: WHO.
86. WHO (1996) World Health Organisation. Task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligospermia in normal men, Fertility and Sterility, 65, 4, 821-29.
87. Wu, F.C.W. (1988) Male contraception: Current status and future prospects, Clinical Endocrinology, 29, 443-65.